HBOC-201 Expanded Access Protocol for Life-threatening Anemia for Whom Allogeneic Blood Transfusion is Not an Option

Expanded Access Protocol Using HBOC-201

The purpose of this protocol is to provide treatment with HBOC-201 to patients with life-threatening anemia for whom blood is not an option. Such patients may also be referred to in this document as patients who refuse blood transfusion (PWRBT). Other patients who potentially may require HBOC-201 treatment include those with red blood cell alloantibodies for whom immunologically compatible red blood cell units cannot be found, although these patients are less common than PWRBT.

Study Overview

• Status: Available
• Conditions: Anemia
• Intervention / Treatment: Drug: HBOC-201

Detailed Description

This is an open label intermediate-size patient population expanded access IND protocol.

Due to our experience with management of severely anemic patients for whom blood is not an option, we anticipate encountering future patients with life-threatening anemia for whom blood is not an option. Blood is not an option in the following circumstances:

• refusal of transfusion
• lack of compatible red blood cells due to alloimmunity

All patients with life-threatening anemia for whom blood is not an option will be treated as per the standard procedure. If those measures are not successful and the life-threatening anemia persists, then at the investigator's discretion treatment with HBOC-201 will then be considered.

• Study Type: Expanded Access

Contacts and Locations

• Study Contact: Name: Mauricio Lynn, MD; Phone Number: 305-585-1178; Email: mlynn@miami.edu

Study Locations

• United States
  • Florida
    • Miami, Florida, United States, 33136
      • Available
      • Jackson Memorial Hospital

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 16 years to 78 years (Adult, Older Adult)
• Accepts Healthy Volunteers: N/A

Description

Inclusion Criteria:

1. Patients ≥ 18 years of age
2. Critically ill patients with hemoglobin < 5 g/dL (or 6-7 g/dL with significant active bleeding), and physiologic evidence of critical ischemia, for example: elevated troponins, altered mental status, acute renal failure, lactic acidosis or evidence of central nervous system acute deficits
3. Patients or their Legally Authorized Representative who are able and willing to provide informed consent

4. Blood is not an option due to:

   • refusal of transfusion
   • lack of compatible red blood cells

Exclusion Criteria:

1. Patients with known hypersensitivity or allergy to beef products
2. Patients with pre-existing uncontrolled hypertension, heart failure, renal failure, circulatory hypervolemia or systemic mastocytosis*
3. Patients who are eligible for blood transfusions
4. Patients who are > 80 years old*
5. Pregnant

6. Lactating

   • on a case by case and quality of life determination

Study Plan

How is the study designed?

Collaborators and Investigators

• Sponsor: Mauricio Lynn
• Investigators: Principal Investigator: Mauricio Lynn, University of Miami

Study record dates

Study Registration Dates

• First Submitted: October 4, 2016
• First Submitted That Met QC Criteria: October 13, 2016
• First Posted (Estimated): October 14, 2016

Study Record Updates

• Last Update Posted (Estimated): November 22, 2023
• Last Update Submitted That Met QC Criteria: November 21, 2023
• Last Verified: November 1, 2023

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Hematologic Diseases; Anemia; Blood Substitutes; HBOC 201
• Other Study ID Numbers: 20160819